ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News/IR

    • Announcement

    • Press

    • Regulatory Disclosure

    • Stock Information

  • 한
  • EN
CONTACT US
  • Main
  • News/IR
  • Press

메디칼타임즈

국내 약가인하·미 관세 이슈 겹친 제약바이오 "해외진출이 답"

  • 01-29-2026
https://www.medicaltimes.com/Main/News/NewsView.html?ID=1167064
Previous
온코크로스, AI 플랫폼 발굴 항암 파이프라인 'OC-212e' 美 특허 등록 02-10-2026
Next
온코크로스, 단백체 분석 기업 '오믹스AI' 투자 01-08-2026
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.